Health Claims on Canadian Food Labels

A regulatory classification with enforcement consequences, not a marketing decision.

A health claim on a food label is a regulatory classification. The Food and Drug Regulations, Health Canada guidance, and CFIA's Industry Labelling Tool sort representations into categories with different evidentiary burdens, different pre-market requirements, and different enforcement consequences. The category a claim falls into is not the marketer's call, and it is often not the category the marketing team had in mind.

The wrong classification can turn a compliance question into a Drug Identification Number question, and a routine label review into a Competition Bureau file. GSJ&Co. does the category work before artwork and builds the substantiation file that defends the claim afterward. Most of the cost lives in the second step. The outcome is decided in the first.

The Claim Hierarchy

The categories matter because they carry different rules.

  • Nutrient content claims describe the level of an energy value or a nutrient. "Source of fibre," "low in saturated fat," "no added sugars," and "reduced sodium" are nutrient content claims. Governed primarily by FDR ss. B.01.500 through B.01.513 and by the Table of Permitted Nutrient Content Statements and Claims, a document incorporated by reference into the FDR. The current Table was published on September 2, 2025 and replaced the table that previously followed section B.01.513 (repealed on the same date). A claim that meets the FDR and Table conditions may be made without pre-market authorization. A claim that does not is prohibited. Comparative claims (light, reduced, lower, fewer) carry additional requirements about the comparison food and the reference amount.

  • Function and nutrient function claims describe a beneficial effect of an energy-yielding nutrient, a vitamin, a mineral, or a food on a normal physiological function. "Calcium aids in the formation and maintenance of bones and teeth" is the archetype. No pre-market authorization, but the claim must be truthful, not misleading, and supported by accepted scientific evidence. It cannot reference a disease, a disorder, or an abnormal physiological state. Health Canada publishes specific wording for several nutrient function claims; deviating from the published wording invites scrutiny.

  • Disease risk reduction claims assert that a food, food constituent, or category reduces the risk of developing a diet-related disease or condition. They sit under FDR ss. B.01.601 through B.01.603. A short list of eligible claims is available under prescribed conditions, including sodium and potassium intake and blood pressure, calcium and vitamin D and osteoporosis, and fruits and vegetables and cancer. Each has its own conditions on food composition, claim wording, and accompanying disclaimers. A disease risk reduction claim that is not on the eligible list cannot be made without first obtaining pre-market authorization to add it.

  • Therapeutic claims assert that a product treats, prevents, mitigates, or cures a disease, disorder, or abnormal physical state. A therapeutic claim positions the product as a drug under the Food and Drugs Act. Once representations push a product into drug territory, the product needs a Drug Identification Number and is on the drug regulatory pathway. For most food companies, this is not a label problem to be solved; it is a category change to be avoided. For the broader classification framework, see product classification.

  • General health and well-being claims ("supports overall wellness," "good for you") sit in a permissive but constrained zone. CFIA's position, reflected in the Industry Labelling Tool, is that vague health claims must still be truthful, not misleading, and supportable. A claim that crosses into disease territory by implication will be treated as disease risk reduction or therapeutic regardless of how the label phrases it.

The hierarchy is not always intuitive from marketing language. "Helps support a healthy heart" reads as a general well-being claim and is often labelled as one; depending on context and adjacent representations, CFIA can read the same wording as an implied disease risk reduction claim about cardiovascular disease. The category is assigned on the totality of the representation.

Substantiation

A nutrient content claim that meets the FDR and the Table of Permitted Nutrient Content Statements and Claims, a function claim, or an eligible disease risk reduction claim made within its prescribed conditions does not require per-product pre-market authorization. It still has to be substantiated.

The standard is not codified as a single test. It draws from Health Canada's scientific evaluation guidance, the CFIA Industry Labelling Tool, and the general requirement under the Food and Drugs Act that food labelling not be false, misleading, or deceptive. A company making a claim needs to be able to produce, on request:

  1. evidence that the food meets the prescribed compositional criteria;

  2. analytical data supporting any nutrient content statement;

  3. the scientific rationale for any function claim;

  4. comprehension or use-context evidence for any non-standard wording.

Claims tend to fail substantiation tests when (a) the claim is technically permitted, but the specific product cannot be substantiated on the specific evidence the company holds; (b) the wording exceeds the eligible claim language by adding a phrase, a comparator, or an implied benefit that takes the representation outside the prescribed form; or (c) the evidence sits in R&D files rather than in a substantiation file the company can produce on request.

Pre-market Authorization for New Disease Risk Reduction Claims

A company that wants to make a disease risk reduction claim that is not already on the eligible list must obtain pre-market authorization from Health Canada. Authorization runs through a regulatory amendment process: a scientific submission to Health Canada's Food Directorate, evaluation of the totality of the evidence, public consultation, and ultimately an amendment to the regulations or to incorporated-by-reference documents.

The submission is heavy. It typically includes:

  • the proposed claim wording;

  • composition criteria for eligible foods;

  • a comprehensive review of the human intervention and observational evidence;

  • mechanistic data where relevant;

  • intake modelling;

  • consumer comprehension analysis;

  • justification for accompanying disclaimers.

Submissions fail when the evidence does not meet the threshold, the proposed conditions of use cannot be substantiated, or the consumer comprehension data does not support the proposed wording.

The companies that pursue this route are generally large enough to support a multi-year scientific and regulatory file with no certainty of approval. For most, the practical route is to determine whether an existing eligible claim can be reframed to fit the product, or whether the marketing objective can be met with a function claim, a nutrient content claim, or a non-claim representation.

The Food/Drug Boundary

A claim that crosses into therapeutic territory pulls the product into the drug regime under the Food and Drugs Act. Section 3 and Schedule A.1 historically restricted claims relating to the prevention, treatment, or cure of certain diseases on foods, cosmetics, and natural health products. The framework has been amended over time; the underlying principle is unchanged. A representation that the product treats, prevents, or cures a disease can re-classify the product. The reclassification is not a labelling defect that can be cured by adjusting a claim. It is a category change: the product needs a Drug Identification Number, a different manufacturing regime, and a different commercial pathway.

The boundary is tested most often in three places:

  • products with strong functional ingredients (botanicals, concentrated extracts, certain vitamins or minerals at elevated levels) where the claim slides toward disease territory;

  • products marketed alongside lifestyle or wellness claims that imply disease management;

  • products positioned as alternatives to over-the-counter drug categories.

The regulator looks at the totality of the representations: brand name, imagery, website copy, and social media context, not just the words on the panel.

Parallel Exposure Under the Competition Act

CFIA is not the only enforcement risk. The Competition Act runs two parallel streams.

  • Section 52 creates a criminal offence for knowingly or recklessly making a false or misleading representation to the public for the purpose of promoting a product.

  • Section 74.01 creates a civil reviewable practice for false or misleading representations more broadly, with no requirement to prove knowledge or recklessness.

The Competition Bureau and CFIA have overlapping but distinct mandates. CFIA can take the FDR path: notices, seizures, and Administrative Monetary Penalties. The Bureau can pursue a representation independently under the Competition Act, with remedies that include consent agreements, civil penalties, and corrective notices.

A claim that fails the FDR analysis often also fails the Competition Act analysis. A claim that is permissible under the FDR but unsupportable on the evidence the company holds can attract Bureau action even if CFIA takes no enforcement step. Claim review has to consider both regulators.

Where Counsel Fits

Pre-launch claim review. Sorting proposed claims into the right category, identifying which require pre-market authorization, which fit an eligible claim, and which need to be reframed or dropped. Most useful before artwork is finalized; reworking a label after a CFIA finding or a Bureau inquiry is materially more expensive than building the claim slate correctly at the outset.

Substantiation file preparation. Building and maintaining the evidence file that supports each claim. Health Canada and CFIA can ask. The Bureau can demand. A claim with no substantiation file is one inquiry away from being withdrawn under pressure.

Disease risk reduction submissions. For companies with the scale to pursue a new disease risk reduction claim, scoping the submission, advising on the evidence dossier, and managing the regulatory process. The decision of whether to pursue is itself useful work.

Food/drug boundary analysis. Whether the totality of a product's representations risks pushing it across the drug boundary, and structuring the marketing around a defensible food classification. Integrates with product classification and, for relevant products, supplemented foods.

Enforcement response. Responding to CFIA findings, Bureau inquiries, and parallel regulatory action. For the broader advertising and marketing framework, see food advertising and marketing law.

GSJ&Co. advises food companies on claim categorization, substantiation file structure, disease risk reduction submissions, the food/drug boundary, and enforcement response before CFIA and the Competition Bureau. Contact info@gsjameson.com or +1 (647) 638-3994.

Primary Authorities

Last updated: April 2026. This page is maintained by GSJ&Co. and updated when there are material changes to the federal health claim framework or to enforcement under the Food and Drug Regulations or the Competition Act.